Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Estes
Lynn
L
Orenstein
Robert
R
D000081:Acetamides / Q000191:economics* / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003428:Cross Infection / Q000188:drug therapy / Q000191:economics; D003661:Decision Support Techniques; D004305:Dose-Response Relationship, Drug; D006801:Humans; D000069349:Linezolid; D016106:Methicillin Resistance; D023303:Oxazolidinones / Q000191:economics* / Q000627:therapeutic use; D011023:Pneumonia, Staphylococcal / Q000188:drug therapy / Q000191:economics*; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D012189:Retrospective Studies; D013211:Staphylococcus aureus / Q000187:drug effects; D015996:Survival Rate; D014640:Vancomycin / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use
D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D014640:Vancomycin; D000069349:Linezolid